ASDERA develops interventions for unmet needs by utilizing a patented computational biostatistics platform to identify complex genetic risk factors in small (from n≈500) epidemiological and 'failed' phase 2/3 studies.

  The ASDERA time-/pipeline:

  1. Validation: Confirmation of known drug targets in epilepsy
    (2013, Pharmacogenomics)
  2. Proof-of-principle: L-fucose in Crohn's disease 
    (in progress, from 2006 dbGaP data)
  3. Autism: A derivative of mefenamic acid against mutism in autism (2014, Nature: Transl. Psychiatry, $500M valuation)
  4. Lysosome function treatments: Intestinally absorbed derivatives of HP-a-cyclodextrin  (pat. pending) against progression of
    - carcinomas (breast cancer,
    neurodegeneration (Alzheimer's, Parkinson's, Huntingtion's, ...) 
  5. - lysosomal storage diseases (NPC, TS, Fabry, Sandhoff, Farber, ...)
  6. Nutritional products: Novel formulation of a-cyclodextrin (pat. pending) for use in dietary supplements and food as
    - 'fasting mimetic' to improve the natural process of aging
  7. - 'adaptive vaccination' to reduce severity of initial infection with
       SARS-CoV-2 while developing COVID-19 immunity.